The use of pergolide, a potent dopamine agonist, in parkinson's disease
| Autor: | Morton Leibowitz, Andreas Neophytides, Russell W. Walker, Virginia Pact, Abraham Lieberman, Govindan Gopinathan, Menek Goldstein |
|---|---|
| Rok vydání: | 1982 |
| Předmět: |
Adult
Male Levodopa Time Factors Parkinson's disease Pharmacology Dopamine agonist law.invention Antiparkinson Agents Random Allocation Double-Blind Method law medicine Humans Pharmacology (medical) Ergolines Aged Pergolide Clinical pharmacology business.industry Drug Synergism Parkinson Disease Middle Aged medicine.disease Ergoline Drug Evaluation Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Clinical Pharmacology and Therapeutics. 32:70-75 |
| ISSN: | 1532-6535 0009-9236 |
| DOI: | 10.1038/clpt.1982.128 |
| Popis: | Pergolide, a semisynthetic ergoline and a potent long-acting adenylcyclase-linked dopamine agonist, was given to 40 patients with advanced Parkinson s disease whose response to levodopa had diminished considerably. The group included 31 patients with marked diurnal oscillations in performance (“wearing off” and/or “on-off” phenomena). Pergolide alone (7 patients) or combined with levodopa (33 patients), resulted in a reduction in disability (P ≤ 0.01) as assessed in both the patients' “on” and “off” periods. Pergolide also resulted in an increase (P ≤ 0.001) in the number of hours in which patients were on from 3.8 (±0.4) to 11.9 (±0.9). The mean daily dose of pergolide was 2.4 mg (range 0.1 to 10.0). The mean duration of the study was 12 mo (range 1 to 24). Pergolide is effective in Parkinson's disease and will change the management of patients whose response to levodopa has diminished. Clinical Pharmacology and Therapeutics (1982) 32, 70–75; doi:10.1038/clpt.1982.128 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text